Dr Reddys Financials
| RDDA Stock | EUR 12.40 0.20 1.64% |
RDDA |
Dr Reddys Stock Summary
Dr Reddys competes with United Breweries, BRAEMAR HOTELS, Fevertree Drinks, Molson Coors, and DALATA HOTEL. Reddys Laboratories Limited operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India. DR REDDYS operates under Drug Manufacturers - Specialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 21966 people.| Instrument | Germany Stock View All |
| Exchange | Frankfurt Exchange |
| ISIN | US2561352038 |
| Business Address | 8-2-337, Road No |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | www.drreddys.com |
| Phone | 91 40 4900 2900 |
| Currency | EUR - Euro |
You should never invest in Dr Reddys without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of RDDA Stock, because this is throwing your money away. Analyzing the key information contained in Dr Reddys' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Dr Reddys Key Financial Ratios
There are many critical financial ratios that Dr Reddys' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Dr Reddys Laboratories reports annually and quarterly.| Return On Equity | 0.18 | |||
| Return On Asset | 0.0949 | |||
| Target Price | 77.85 | |||
| Beta | 0.24 | |||
| Z Score | 0.6 |
RDDA Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Dr Reddys's current stock value. Our valuation model uses many indicators to compare Dr Reddys value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Dr Reddys competition to find correlations between indicators driving Dr Reddys's intrinsic value. More Info.Dr Reddys Laboratories is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.54 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Dr Reddys Laboratories is roughly 1.87 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Dr Reddys' earnings, one of the primary drivers of an investment's value.Dr Reddys Laboratories Systematic Risk
Dr Reddys' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Dr Reddys volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Dr Reddys Laboratories correlated with the market. If Beta is less than 0 Dr Reddys generally moves in the opposite direction as compared to the market. If Dr Reddys Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Dr Reddys Laboratories is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Dr Reddys is generally in the same direction as the market. If Beta > 1 Dr Reddys moves generally in the same direction as, but more than the movement of the benchmark.
Dr Reddys March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Dr Reddys help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Dr Reddys Laboratories. We use our internally-developed statistical techniques to arrive at the intrinsic value of Dr Reddys Laboratories based on widely used predictive technical indicators. In general, we focus on analyzing RDDA Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Dr Reddys's daily price indicators and compare them against related drivers.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 9.3 | |||
| Value At Risk | (3.03) | |||
| Potential Upside | 2.29 |
Complementary Tools for RDDA Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |